ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL),…
News
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Alvotech and Advanz to commercialise biosimilars in Europe
FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review
Astellas and Evopoint sign ADC licensing deal
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
HHS cancels $766m bird flu vaccine contract with Moderna
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities
